,address1,city,state,zip,country,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4342 - 97 street NW,Edmonton,AB,T6E 5R9,Canada,https://www.questpharmatech.com,Biotechnology,Healthcare,"Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.","{'maxAge': 1, 'name': 'Dr. Ragupathy  Madiyalakan Ph.D.', 'title': 'CEO & Director', 'fiscalYear': 2023, 'totalPay': 158800, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.015,0.04,0.015,0.015,0.015,0.04,0.015,0.015,0.0,0.799713,225625,225625,3639,0,0,7508010,0.015,0.0762,0.03,0.045645,0.0,0.0,USD,3246288,0.0,138763782,169128992,0.17056,0.0,0.462,0.03246753,1675123200,1706659200,1682812800,-11456453,-0.05,-3.623,PNK,EQUITY,QPTFF,QPTFF,QUEST PHARMATECH INC,Quest PharmaTech Inc.,1535117400,America/New_York,EDT,-14400000,0.015,none,90650,0.001,-895919,800000,0.311,0.336,1.025,-0.0066299997,-0.13677,-561356,-579289,0.0,0.0,0.0,CAD,
1,4342 - 97 street NW,Edmonton,AB,T6E 5R9,Canada,https://www.questpharmatech.com,Biotechnology,Healthcare,"Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.","{'maxAge': 1, 'name': 'Mr. Pierre  Vermette C.A., CPA', 'title': 'Chief Financial Officer', 'fiscalYear': 2023, 'totalPay': 54780, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.015,0.04,0.015,0.015,0.015,0.04,0.015,0.015,0.0,0.799713,225625,225625,3639,0,0,7508010,0.015,0.0762,0.03,0.045645,0.0,0.0,USD,3246288,0.0,138763782,169128992,0.17056,0.0,0.462,0.03246753,1675123200,1706659200,1682812800,-11456453,-0.05,-3.623,PNK,EQUITY,QPTFF,QPTFF,QUEST PHARMATECH INC,Quest PharmaTech Inc.,1535117400,America/New_York,EDT,-14400000,0.015,none,90650,0.001,-895919,800000,0.311,0.336,1.025,-0.0066299997,-0.13677,-561356,-579289,0.0,0.0,0.0,CAD,
2,4342 - 97 street NW,Edmonton,AB,T6E 5R9,Canada,https://www.questpharmatech.com,Biotechnology,Healthcare,"Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.","{'maxAge': 1, 'name': 'Mr. Roger  Andrews', 'title': 'Head of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.015,0.04,0.015,0.015,0.015,0.04,0.015,0.015,0.0,0.799713,225625,225625,3639,0,0,7508010,0.015,0.0762,0.03,0.045645,0.0,0.0,USD,3246288,0.0,138763782,169128992,0.17056,0.0,0.462,0.03246753,1675123200,1706659200,1682812800,-11456453,-0.05,-3.623,PNK,EQUITY,QPTFF,QPTFF,QUEST PHARMATECH INC,Quest PharmaTech Inc.,1535117400,America/New_York,EDT,-14400000,0.015,none,90650,0.001,-895919,800000,0.311,0.336,1.025,-0.0066299997,-0.13677,-561356,-579289,0.0,0.0,0.0,CAD,
3,4342 - 97 street NW,Edmonton,AB,T6E 5R9,Canada,https://www.questpharmatech.com,Biotechnology,Healthcare,"Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.","{'maxAge': 1, 'name': 'Mr. Douglas C. Bachman', 'age': 68, 'title': 'VP of Corp. Devel.', 'yearBorn': 1954, 'fiscalYear': 2004, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.015,0.04,0.015,0.015,0.015,0.04,0.015,0.015,0.0,0.799713,225625,225625,3639,0,0,7508010,0.015,0.0762,0.03,0.045645,0.0,0.0,USD,3246288,0.0,138763782,169128992,0.17056,0.0,0.462,0.03246753,1675123200,1706659200,1682812800,-11456453,-0.05,-3.623,PNK,EQUITY,QPTFF,QPTFF,QUEST PHARMATECH INC,Quest PharmaTech Inc.,1535117400,America/New_York,EDT,-14400000,0.015,none,90650,0.001,-895919,800000,0.311,0.336,1.025,-0.0066299997,-0.13677,-561356,-579289,0.0,0.0,0.0,CAD,
4,4342 - 97 street NW,Edmonton,AB,T6E 5R9,Canada,https://www.questpharmatech.com,Biotechnology,Healthcare,"Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.","{'maxAge': 1, 'name': 'Mr. Thomas  Woo', 'title': 'VP of Product Devel.', 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.015,0.04,0.015,0.015,0.015,0.04,0.015,0.015,0.0,0.799713,225625,225625,3639,0,0,7508010,0.015,0.0762,0.03,0.045645,0.0,0.0,USD,3246288,0.0,138763782,169128992,0.17056,0.0,0.462,0.03246753,1675123200,1706659200,1682812800,-11456453,-0.05,-3.623,PNK,EQUITY,QPTFF,QPTFF,QUEST PHARMATECH INC,Quest PharmaTech Inc.,1535117400,America/New_York,EDT,-14400000,0.015,none,90650,0.001,-895919,800000,0.311,0.336,1.025,-0.0066299997,-0.13677,-561356,-579289,0.0,0.0,0.0,CAD,
